An Otsuka Pharmaceutical Co. Ltd. patent describes pyrazolo[1,5-a]pyrimidine lysophosphatidic acid receptor 2 (LPAR2; EDG4) antagonists reported to be useful for the treatment of atopic dermatitis, psoriasis, eczema, scleroderma and pruritus, among others.
Jiangsu Hengrui Medicine Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have identified nitrogen-containing heterocyclic compounds acting as poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors reported to be useful for the treatment of cancer.
Innocure Therapeutics Inc. has synthesized piperidinedione derivatives acting as proteolysis targeting chimeric (PROTACs) compounds comprising an E3 ubiquitin ligase cereblon (CRBN) binding moiety covalently linked to hepatocyte growth factor receptor (HGFR; MET; c-MET)-targeting moiety via linker reported to be useful for the treatment of cancer.
Korean Research Institute of Bioscience and Biotechnology has described triterpenoid saponins isolated from Spinacia oleracea (spinach) reported to be useful for the treatment of inflammation.
Astex Therapeutics Ltd. and Taiho Pharmaceutical Co. Ltd. have divulged GTPase KRAS (G12C mutant), (G12D mutant) and/or (G12V mutant) inhibitors reported to be useful for the treatment of cancer.
Emory University has identified deuterated and/or methylated N4-hydroxycytidine (NHC) analogues reported to be useful for the treatment of viral infections.
Lunac Therapeutics Ltd. has synthesized coagulation factor XII (FXIIa) inhibitors reported to be useful for the treatment of arthritis, Alzheimer's disease, disseminated intravascular coagulation, pulmonary embolism, myocardial infarction, diabetic retinopathy, stroke and deep venous thrombosis, among others.
Nanjing Kangyi Biomedical Center LP has disclosed compounds with dipyrrolopyridine structure acting as Janus kinase (JAK) inhibitors reported to be useful for the treatment of cancer, asthma, atopic dermatitis, psoriasis, rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus and inflammatory bowel disease, among others.
Xuanzhu Pharma Co. Ltd. has described protein mono-ADP-ribosyltransferase TIPARP (PARP7; ARTD14) inhibitors reported to be useful for the treatment of cancer.
RSS